Valuation: Monopar Therapeutics Inc.

Market Cap 72Cr 63Cr 58Cr 54Cr 100.83Cr 6.87TCr 102.66Cr 687.18Cr 269.06Cr 3.41TCr 270.24Cr 264.32Cr 11TCr P/E 2026 *
-46.6x
P/E 2027 * -31x
Enterprise Value 60Cr 52Cr 48Cr 45Cr 84Cr 5.74TCr 86Cr 573.96Cr 224.73Cr 2.85TCr 225.71Cr 220.77Cr 9.58TCr EV / Sales 2026 *
-
EV / Sales 2027 * 38.3x
Free-Float
76.58%
Yield 2026 *
-
Yield 2027 * -
1 day+6.71%
1 week+6.90%
Current month+22.04%
1 month+22.04%
3 months+116.67%
6 months+87.14%
Current year+73.04%
1 week 103
Extreme 103
113.5
1 month 88.33
Extreme 88.33
116.64
Current year 50.07
Extreme 50.07
116.64
1 year 29.18
Extreme 29.18
116.64
3 years 1.37
Extreme 1.3695
116.64
5 years 1.37
Extreme 1.3695
116.64
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
+7.66%+6.90%+164.87%+2,949.80% 72Cr
-0.80%+5.16%-0.70%+12.87% 4.89TCr
-4.08%+14.24%+23.65%+5.85% 4.07TCr
+4.27%-0.31%+408.36%+616.84% 3.85TCr
-1.95%-1.90%+6.88%+49.65% 3.64TCr
+5.56%+11.70%+11.64%+51.50% 2.84TCr
-1.37%-1.82% - - 1.66TCr
-0.97%-4.61%+32.00%+128.25% 1.63TCr
-6.85%-2.52%-8.53%-33.96% 1.36TCr
-0.06%+3.75%+3.81%+9.62% 1.36TCr
Average +0.11%+5.01%+71.33%+421.16% 2.54TCr
Weighted average by Cap. -0.20%+7.17%+75.00%+133.82%

Financials

2026 *2027 *
Net sales - 1.58Cr 1.38Cr 1.28Cr 1.18Cr 2.22Cr 151.23Cr 2.26Cr 15Cr 5.92Cr 75Cr 5.95Cr 5.82Cr 252.58Cr
Net income -2.02Cr -1.75Cr -1.63Cr -1.5Cr -2.83Cr -192.48Cr -2.88Cr -19Cr -7.54Cr -96Cr -7.57Cr -7.41Cr -321.47Cr -3.57Cr -3.1Cr -2.88Cr -2.66Cr -5.01Cr -341.18Cr -5.1Cr -34Cr -13Cr -169.45Cr -13Cr -13Cr -569.84Cr
Net Debt -12Cr -10Cr -9.56Cr -8.82Cr -17Cr -1.13TCr -17Cr -113.22Cr -44Cr -562.17Cr -45Cr -44Cr -1.89TCr -11Cr -9.76Cr -9.06Cr -8.36Cr -16Cr -1.07TCr -16Cr -107.27Cr -42Cr -532.65Cr -42Cr -41Cr -1.79TCr
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
30/26/30 $113.00 +5.19% 1,42,904
29/26/29 $107.43 -1.53% 3,57,181
28/26/28 $109.09 -1.12% 5,28,971
27/26/27 $110.33 +0.42% 3,39,767
24/26/24 $109.87 +3.95% 2,29,818
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
107.42USD
Average target price
116.85USD
Spread / Average Target
+8.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock